Humana EBIT

The latest EBIT for HUM is $2.3B as of June 2026. That compares with $2.8B in the prior-year period — down 19.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Humana's historical trend and sector peers before judging valuation or financial health.

Over the past year, HUM's EBIT moved from $2.8B to $2.3B — a 19.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Humana's operating scale or balance-sheet position.

Against Healthcare companies, HUM currently prints $2.3B for EBIT, while the sector average sits near $22B. That is roughly 89.9% below the sector mean. Large gaps often invite a closer look at Humana's growth, margins, and balance sheet.

A EBIT figure of $2.3B for HUM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting HUM's EBIT ($2.3B), review year-over-year change from $2.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.